Yazar "Demir-Dora, Devrim" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
  • [ X ]
    Öğe
    Combination Treatment with Cromolyn Sodium and Masitinib Displays Cell-Protective Effect and Shows Additive Anti-Oxidative Actions on an in vitro Neurodegenerative Model
    (Springer/Plenum Publishers, 2021) Erol, A. Yasemin Goksu; Kocanci, Fatma Gonca; Demir-Dora, Devrim; Uysal, Hilmi
    [Abstract Not Available]
  • [ X ]
    Öğe
    Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration
    (Wiley, 2024) Goksu, Azize Yasemin; Kocanci, Fatma Gonca; Akinci, Ersin; Demir-Dora, Devrim; Erendor, Fulya; Sanlioglu, Salih; Uysal, Hilmi
    A common pathological hallmark of neurodegenerative disorders is neuronal cell death, accompanied by neuroinflammation and oxidative stress. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. The gene therapy field shows long-term promise for treating a wide range of neurodegenerative diseases (ND). In this study, we aimed to investigate the in vitro efficacy of transduction of microglia using lentiviral gene therapy vectors encoding VIP (LentiVIP). Additionally, we tested the protective effects of the secretome derived from LentiVIP-infected immortalized human microglia HMC3 cells, and cells treated with Synthetic VIP (SynVIP), against toxin-induced neurodegeneration. First, LentiVIP, which stably expresses VIP, was generated and purified. VIP secretion in microglial conditioned media (MG CM) for LentiVIP-infected HMC3 microglia cells was confirmed. Microglia cells were activated with lipopolysaccharide, and groups were formed as follows: 1) Control, 2) SynVIP-treated, or 3) LentiVIP-transduced. These MG CM were applied on an in vitro neurodegenerative model formed by differentiated (d)-SH-SY5Y cells. Then, cell survival analysis and apoptotic nuclear staining, besides measurement of oxidative/inflammatory parameters in CM of cells were performed. Activated MG CM reduced survival rates of both control and toxin-applied (d)-SH-SY5Y cells, whereas LentiVIP-infected MG CM and SynVIP-treated ones exhibited better survival rates. These findings were supported by apoptotic nuclear evaluations of (d)-SH-SY5Y cells, alongside oxidative/inflammatory parameters in their CM. LentiVIP seems worthy of further studies for the treatment of ND because of the potential of gene therapy to treat diseases effectively with a single injection. Cultured microglial cells were activated with LPS, and then grouped as: 1) Control, 2) SynVIP-treated, or 3) LentiVIP-transduced microglia. Subsequently, conditioned media of microglial groups were applied on differentiated-SH-SY5Y cells that were exposed to MPTP (a neurotoxin) or not. Several analysis and tests were performed to investigate the protective effects of SynVIP or LentiVIP against toxicity of MPTP or microglial secretome. image
  • Küçük Resim
    Öğe
    SARS-CoV-2 Mutations and their Viral Variants
    (2022) Coşar, Begüm; Karagülleoğlu, Zeynep Yağmur; Ünal, Sinan; İnce, Ahmet Turan; Uncuoğlu, Dilruba Beyza; Tuncer, Gizem; Kılınç, Buğrahan Regaip; Özkan, Yunus Emre; Özkoç, Hikmet Ceyda; Demir, İbrahim Naki; Eker, Ali; Karagöz, Feyzanur; Şimşek, Said Yasin; Yaşar, Bünyamin; Pala, Mehmetcan; Demir, Ayşegül; Atak, İrem Naz; Mendi, Ayşegül Hanife; Bengi, Vahdi Umut; Cengiz Seval, Güldane; Güneş Altuntaş, Evrim; Kılıç, Pelin; Demir-Dora, Devrim
    Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel mutations continue appearing at the scene, naturally, new variants are increasingly observed. Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications. The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more than one viral protein. In this review, a literature survey in the scope of the increasing SARS-CoV-2 mutations and the viral variations is conducted. In the light of current knowledge, the various disguises of the mutant SARS-CoV-2 forms and their apparent differences from the original strain are examined as they could possibly aid in finding the most appropriate therapeutic approaches.